Regencell Bioscience Holdings Limited RGC
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is a CNS/neurology/psychiatry drug developer. Its lead program, Standardized TCM Formula for ADHD and ASD, is in Pre-clinical for Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Standardized TCM Formula for ADHD and ASD | ADHD and ASD | unclear | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.